Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:18729445rdf:typepubmed:Citationlld:pubmed
pubmed-article:18729445lifeskim:mentionsumls-concept:C0597357lld:lifeskim
pubmed-article:18729445lifeskim:mentionsumls-concept:C0016011lld:lifeskim
pubmed-article:18729445lifeskim:mentionsumls-concept:C0040018lld:lifeskim
pubmed-article:18729445lifeskim:mentionsumls-concept:C0441655lld:lifeskim
pubmed-article:18729445lifeskim:mentionsumls-concept:C0542341lld:lifeskim
pubmed-article:18729445lifeskim:mentionsumls-concept:C0021469lld:lifeskim
pubmed-article:18729445lifeskim:mentionsumls-concept:C0456387lld:lifeskim
pubmed-article:18729445lifeskim:mentionsumls-concept:C0679622lld:lifeskim
pubmed-article:18729445lifeskim:mentionsumls-concept:C1554184lld:lifeskim
pubmed-article:18729445lifeskim:mentionsumls-concept:C0205314lld:lifeskim
pubmed-article:18729445lifeskim:mentionsumls-concept:C0243072lld:lifeskim
pubmed-article:18729445lifeskim:mentionsumls-concept:C0205198lld:lifeskim
pubmed-article:18729445pubmed:issue18lld:pubmed
pubmed-article:18729445pubmed:dateCreated2008-9-19lld:pubmed
pubmed-article:18729445pubmed:abstractText3,4-Dihydro-2 H-1,4-benzoxazine derivatives possessing both thrombin inhibitory and glycoprotein IIb/IIIa (GPIIb/IIIa) receptor antagonistic activities were obtained by combining mimetics of the d-Phe-Pro-Arg pharmacophore of thrombin inhibitors and the Arg-Gly-Asp pharmacophore of GPIIb/IIIa receptor antagonists in the same low molecular weight peptidomimetic compound. Systematic variation of the position of substituents around the 3,4-dihydro- 2H-1,4-benzoxazine nucleus, the distance between the carboxylate and amidine moieties, together with additional substituents to fill the thrombin S 2 and S 3 pockets resulted in compounds displaying submicromolar inhibition constants ( K i) for thrombin and submicromolar IC 50 for inhibition of binding of fibrinogen to platelet GPIIb/IIIa receptor. Some of these compounds, such as 17a, 17b, 17d, and 17h possessing a well balanced activity at both targets, are a good starting point for further optimization. Incorporation of anticoagulant and platelet antiaggregatory activity in the same molecule constitutes a promising approach toward novel antithrombotic agents.lld:pubmed
pubmed-article:18729445pubmed:languageenglld:pubmed
pubmed-article:18729445pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18729445pubmed:citationSubsetIMlld:pubmed
pubmed-article:18729445pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18729445pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18729445pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18729445pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18729445pubmed:statusMEDLINElld:pubmed
pubmed-article:18729445pubmed:monthSeplld:pubmed
pubmed-article:18729445pubmed:issn1520-4804lld:pubmed
pubmed-article:18729445pubmed:authorpubmed-author:StegnarMojcaMlld:pubmed
pubmed-article:18729445pubmed:authorpubmed-author:KikeljDanijel...lld:pubmed
pubmed-article:18729445pubmed:authorpubmed-author:IlasJanezJlld:pubmed
pubmed-article:18729445pubmed:authorpubmed-author:JakopinZigaZlld:pubmed
pubmed-article:18729445pubmed:authorpubmed-author:BorstnarTinaTlld:pubmed
pubmed-article:18729445pubmed:issnTypeElectroniclld:pubmed
pubmed-article:18729445pubmed:day25lld:pubmed
pubmed-article:18729445pubmed:volume51lld:pubmed
pubmed-article:18729445pubmed:ownerNLMlld:pubmed
pubmed-article:18729445pubmed:authorsCompleteYlld:pubmed
pubmed-article:18729445pubmed:pagination5617-29lld:pubmed
pubmed-article:18729445pubmed:meshHeadingpubmed-meshheading:18729445...lld:pubmed
pubmed-article:18729445pubmed:meshHeadingpubmed-meshheading:18729445...lld:pubmed
pubmed-article:18729445pubmed:meshHeadingpubmed-meshheading:18729445...lld:pubmed
pubmed-article:18729445pubmed:meshHeadingpubmed-meshheading:18729445...lld:pubmed
pubmed-article:18729445pubmed:meshHeadingpubmed-meshheading:18729445...lld:pubmed
pubmed-article:18729445pubmed:meshHeadingpubmed-meshheading:18729445...lld:pubmed
pubmed-article:18729445pubmed:meshHeadingpubmed-meshheading:18729445...lld:pubmed
pubmed-article:18729445pubmed:meshHeadingpubmed-meshheading:18729445...lld:pubmed
pubmed-article:18729445pubmed:meshHeadingpubmed-meshheading:18729445...lld:pubmed
pubmed-article:18729445pubmed:meshHeadingpubmed-meshheading:18729445...lld:pubmed
pubmed-article:18729445pubmed:meshHeadingpubmed-meshheading:18729445...lld:pubmed
pubmed-article:18729445pubmed:year2008lld:pubmed
pubmed-article:18729445pubmed:articleTitle3,4-Dihydro-2H-1,4-benzoxazine derivatives combining thrombin inhibitory and glycoprotein IIb/IIIa receptor antagonistic activity as a novel class of antithrombotic compounds with dual function.lld:pubmed
pubmed-article:18729445pubmed:affiliationFaculty of Pharmacy, University of Ljubljana, Askerceva 7, SI-1000 Ljubljana, Slovenia.lld:pubmed
pubmed-article:18729445pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:18729445pubmed:publicationTypeIn Vitrolld:pubmed
pubmed-article:18729445pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...http://linkedlifedata.com/r...pubmed-article:18729445lld:chembl